These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25904020)

  • 1. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.
    Uher T; Horakova D; Kalincik T; Bergsland N; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
    Eur J Neurol; 2015 Jul; 22(7):1113-23. PubMed ID: 25904020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
    Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
    Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI correlates of disability progression in patients with CIS over 48 months.
    Uher T; Horakova D; Bergsland N; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
    Neuroimage Clin; 2014; 6():312-9. PubMed ID: 25379444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome.
    Varosanec M; Uher T; Horakova D; Hagemeier J; Bergsland N; Tyblova M; Seidl Z; Vaneckova M; Krasensky J; Dwyer MG; Havrdova E; Zivadinov R
    AJNR Am J Neuroradiol; 2015 Aug; 36(8):1457-64. PubMed ID: 26113068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
    Weinstock-Guttman B; Zivadinov R; Horakova D; Havrdova E; Qu J; Shyh G; Lakota E; O'Connor K; Badgett D; Tamaño-Blanco M; Tyblova M; Hussein S; Bergsland N; Willis L; Krasensky J; Vaneckova M; Seidl Z; Ramanathan M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1186-91. PubMed ID: 23595944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
    Simon JH; Kinkel RP; Kollman C; O'Connor P; Fisher E; You X; Hyde R;
    Mult Scler; 2015 Apr; 21(4):415-22. PubMed ID: 25344370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Uher T; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Ramasamy D; Zivadinov R; Havrdova E; Kalincik T; Horakova D
    Mult Scler; 2017 Jan; 23(1):51-61. PubMed ID: 27053635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.
    Kalincik T; Vaneckova M; Tyblova M; Krasensky J; Seidl Z; Havrdova E; Horakova D
    PLoS One; 2012; 7(11):e50101. PubMed ID: 23166826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
    Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
    Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Uher T; Horakova D; Tyblova M; Zeman D; Krasulova E; Mrazova K; Seidl Z; Vaneckova M; Krasensky J; Weinstock-Guttman B; Ramanathan M; Havrdova E; Zivadinov R
    Mult Scler; 2016 May; 22(6):770-81. PubMed ID: 26362893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
    N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis.
    Dupuy SL; Khalid F; Healy BC; Bakshi S; Neema M; Tauhid S; Bakshi R
    BMC Med Imaging; 2016 Oct; 16(1):56. PubMed ID: 27716096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
    O'Connor P; Kinkel RP; Kremenchutzky M
    Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D as an early predictor of multiple sclerosis activity and progression.
    Ascherio A; Munger KL; White R; Köchert K; Simon KC; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Radü EW; Sandbrink R; Kappos L; Pohl C
    JAMA Neurol; 2014 Mar; 71(3):306-14. PubMed ID: 24445558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
    Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
    Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.